tetano
Editor, Senior Moderator
Nat Rev Immunol
. 2021 Apr 19.
doi: 10.1038/s41577-021-00542-x. Online ahead of print.
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C Taylor[SUP] 1 [/SUP], Andrew C Adams[SUP] 2 [/SUP], Matthew M Hufford[SUP] 2 [/SUP], Inmaculada de la Torre[SUP] 2 [/SUP], Kevin Winthrop[SUP] 3 [/SUP], Robert L Gottlieb[SUP] 4 5 [/SUP]
Affiliations
Abstract
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials. With the US Food and Drug Administration recently granting emergency use authorizations for neutralizing mAbs in non-hospitalized patients with mild-to-moderate COVID-19, there is an urgent need to discuss the broader potential of these novel therapies and to develop strategies to deploy them effectively in clinical practice, given limited initial availability. Here, we review the precedent for passive immunization and lessons learned from using antibody therapies for viral infections such as respiratory syncytial virus, Ebola virus and SARS-CoV infections. We then focus on the deployment of convalescent plasma and neutralizing mAbs for treatment of SARS-CoV-2. We review specific clinical questions, including the rationale for stratification of patients, potential biomarkers, known risk factors and temporal considerations for optimal clinical use. To answer these questions, there is a need to understand factors such as the kinetics of viral load and its correlation with clinical outcomes, endogenous antibody responses, pharmacokinetic properties of neutralizing mAbs and the potential benefit of combining antibodies to defend against emerging viral variants.
. 2021 Apr 19.
doi: 10.1038/s41577-021-00542-x. Online ahead of print.
Neutralizing monoclonal antibodies for treatment of COVID-19
Peter C Taylor[SUP] 1 [/SUP], Andrew C Adams[SUP] 2 [/SUP], Matthew M Hufford[SUP] 2 [/SUP], Inmaculada de la Torre[SUP] 2 [/SUP], Kevin Winthrop[SUP] 3 [/SUP], Robert L Gottlieb[SUP] 4 5 [/SUP]
Affiliations
- PMID: 33875867
- DOI: 10.1038/s41577-021-00542-x
Abstract
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials. With the US Food and Drug Administration recently granting emergency use authorizations for neutralizing mAbs in non-hospitalized patients with mild-to-moderate COVID-19, there is an urgent need to discuss the broader potential of these novel therapies and to develop strategies to deploy them effectively in clinical practice, given limited initial availability. Here, we review the precedent for passive immunization and lessons learned from using antibody therapies for viral infections such as respiratory syncytial virus, Ebola virus and SARS-CoV infections. We then focus on the deployment of convalescent plasma and neutralizing mAbs for treatment of SARS-CoV-2. We review specific clinical questions, including the rationale for stratification of patients, potential biomarkers, known risk factors and temporal considerations for optimal clinical use. To answer these questions, there is a need to understand factors such as the kinetics of viral load and its correlation with clinical outcomes, endogenous antibody responses, pharmacokinetic properties of neutralizing mAbs and the potential benefit of combining antibodies to defend against emerging viral variants.